PatientsVille.com Logo

DYSKINESIA and Seroquel

PatientsVille

DYSKINESIA Symptoms and Causes

Movement disorders are neurologic conditions that cause problems with movement, such as

  • Increased movement that can be voluntary (intentional) or involuntary (unintended)
  • Decreased or slow voluntary movement

There are many different movement disorders. Some of the more common types include

  • Ataxia, the loss of muscle coordination
  • Dystonia, in which involuntary contractions of your muscles cause twisting and repetitive movements. The movements can be painful.
  • Huntington's disease, an inherited disease that causes nerve cells in certain parts of the brain to waste away. This includes the nerve cells that help to control voluntary movement.
  • Parkinson's disease, which is disorder that slowly gets worse over time. It causes tremors, slowness of movement, and trouble walking.
  • Tourette syndrome, a condition which causes people to make sudden twitches, movements, or sounds (tics)
  • Tremor and essential tremor, which cause involuntary trembling or shaking movements. The movements may be in one or more parts of your body.

Causes of movement disorders include

  • Genetics
  • Infections
  • Medicines
  • Damage to the brain, spinal cord, or peripheral nerves
  • Metabolic disorders
  • Stroke and vascular diseases
  • Toxins

Treatment varies by disorder. Medicines can cure some disorders. Others get better when an underlying disease is treated. Often, however, there is no cure. In that case, the goal of treatment is to improve symptoms and relieve pain.

Check out the latest treatments for DYSKINESIA

DYSKINESIA treatment research studies

Seroquel clinical trials, surveys and public health registries


Find Drug Side Effect reports



Seroquel Side Effects

Diabetes Mellitus (6103)
Type 2 Diabetes Mellitus (3575)
Insomnia (2241)
Pancreatitis (1939)
Blood Cholesterol Increased (1705)
Weight Increased (1696)
Obesity (1197)
Diabetes Mellitus Inadequate Control (1084)
Diabetic Ketoacidosis (1083)
Depression (1046)
Hyperglycaemia (1037)
Diabetic Neuropathy (1010)
Somnolence (997)
Anxiety (972)
Malaise (971)
Off Label Use (948)
Feeling Abnormal (830)
Blood Triglycerides Increased (806)
Suicidal Ideation (805)
Diabetic Coma (803)
Convulsion (757)
Death (753)
Neuropathy Peripheral (744)
Tardive Dyskinesia (696)
Dizziness (683)
Type 1 Diabetes Mellitus (667)
Hyperlipidaemia (662)
Chest Pain (641)
Hypertension (632)
Fall (631)
Fatigue (612)
Headache (611)
Overdose (594)
Suicide Attempt (564)
Back Pain (547)
Bipolar Disorder (519)
Nausea (492)
Agitation (488)
Tremor (449)
Dyspnoea (437)
Confusional State (432)
Loss Of Consciousness (403)
Vomiting (395)
Mental Disorder (383)
Blood Glucose Increased (382)
Abdominal Pain (378)
Cardiac Disorder (373)
Cerebrovascular Accident (370)
Asthenia (368)
Aggression (359)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After taking 300 mgm a day of seroquel, I gained 30 lbs over a period of 3 months with all the symptoms of metabolic syndrome. Now I am unable to lose that weight even though I no longer take the medicati9on

After taking Seroquel for about two weeks, I came down with quite serious laryngitis. I've had it for about a week and it is not getting any better. I don't have a cold or sore throat and can't think of any other reason for this. Could this be cau

Check out my med list; kind like a handbook isn't it?

Doing range of motion exercises on the neck with the head is an excellent way of treating cronic insomonia. >:o O:-)

I also had to increase the weight for my pendulum exercises to make easier to adjust my shoulder. :)

I also had to raise my arms up and down behind my head in order to adjust the top of my neck.

I am having the same experience. I also had been taking Seroquel for about 2 weeks when I began to lose my voice. I am researching today because my laryngitis is practically 100% today.

I Believe Seroquel killed my husband. He tried to get help with depression and suiside and seroquel made him worse. I totally believe this awful drug killed him and he was only 45. I miss him terribly and hope I can help to keep suiside patients off

I had such severe side effects I thought I was going insane. My husband even got out the video camera to show me how bad it was. I rocked and rocked back and forth, my entire body shook involuntarily, I paced, I didn't sleep,I couldn't rest or relax

I have been taking seroquel and zyban. i have two children, and trying for another. When i gave birth to my children i was on other medication. Since on this combination of seroquel and zyban i cannot seem to ovulate.

After taking Modafinil 200mg for 4 days I suffered an episode of hypertonia that left me collapsed on the floor and unable to move or speak. I remained in spasm for about 5 minutes, followed by a period of extreme fatigue. I had dyskinesia for a furt

My 82 year old dad was placed on vesicare. He was healthy except for post polio syndrome and took only aspirin. He developed an acute anti-cholinergic reactions with tardive dyskinesia, hallucinations, confusion and increased motor weakness. His sy

DYSKINESIA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting ADS-5102 for the Treatment of Levodopa Induced Dyskinesia (EASE LID Study)
Conditions: Dyskinesia;   Levodopa Induced Dyskinesia (LID);   Parkinson's Disease
Intervention: Drug: ADS-5102
Outcome Measures: Change in the Unified Dyskinesia Rating Scale (UDysRS) score;   Change in the standardized PD home diary (ON time without Dyskinesia, ON time with troublesome Dyskinesia, OFF time);   Change in the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS);   Clinician's Global Impression of Change in overall PD symptoms
2 Not yet recruiting Efficacy and Safety of Amantadine ER Tablets to Treat Parkinson's Disease Patients With Levodopa Induced Dyskinesia.
Conditions: Parkinson's Disease;   Levodopa Induced Dyskinesia (LID)
Interventions: Drug: Amantadine ER Tablets;   Drug: Placebo Tablets for Amantadine ER Tablets
Outcome Measures: Unified Dyskinesia Rating Scale (UDysRS);   Mobility State Self-Assessment (Subject Diary Cards);   MDS-UPDRS;   Fatigue Severity Scale
3 Not yet recruiting Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias
Conditions: Parkinson's Disease;   Levodopa Induced Dyskinesia (LID)
Interventions: Drug: Amantadine HCl ER (ALLAY-LID II);   Drug: Placebo
Outcome Measures: Unified Dyskinesia Rating Scale;   Mobility State Self Assessment (Subject Diary Cards);   Mobility State Self-Assessment (Subject Diary Cards);   MDS-Unified Parkinson's Disease Rating Scale;   Fatigue Severity Scale
4 Recruiting Topiramate as an Adjunct to Amantadine in the Treatment of Dyskinesia in Parkinson's Disease
Conditions: Idiopathic Parkinson's Disease;   Drug Induced Dyskinesia
Intervention: Drug: Topiramate
Outcome Measures: The Unified Dyskinesia Rating Scale (UDysRS);   Clinical Global Impression - Change score
5 Recruiting Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Conditions: Dyskinesia;   Parkinson's Disease
Interventions: Drug: AVP-923-45;   Drug: Placebo
Outcome Measures: Unified Dyskinesia Rating Scale (UDysRS), part 3;   UDysRS, part 4;   Movement Disorder Society- Unified Parkinson's Disease Rating Scale (MDS-UPDRS), part III-motor score;   Bradykinesia;   MDS-UPDRS part I, II, and IV;   UDysRS part 1 and 2;   PD Motor Diary
6 Recruiting A Feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MR Guided Focused Ultrasound for Unilateral Pallidotomy in the Treatment of Dyskinesia of Parkinson's Disease
Condition: Levodopa Induced Dyskinesia in Patients With Parkinson's Disease
Intervention: Device: transcranial magnetic resonance guided focused ultrasound pallidotomy
Outcome Measure: the unified Dyskinesia rating scale (UdysRS) and UPDRS part IV
7 Recruiting Inflammatory and Microbiologic Markers in Sputum: Comparing Cystic Fibrosis With Primary Ciliary Dyskinesia
Conditions: Cystic Fibrosis;   Primary Ciliary Dyskinesia
Interventions: Procedure: Sputum Collection;   Procedure: Pulmonary Function Testing;   Procedure: Exhaled Nitric Oxide
Outcome Measures: Change in sputum bacterial colony count;   Airway Inflammatory Profile;   Culture, identification, and antibiotic susceptibility pattern of respiratory pathogens from sputum samples;   Tolerability and need for sputum induction in Cystic Fibrosis (CF) patients in comparison to Primary Ciliary Dyskinesia (PCD) patients;   Change in forced expiratory volume in 1 second (FEV1) in response to a treatment course of antibiotics for pulmonary exacerbation.;   Other markers of airway inflammation
8 Unknown  Aripiprazole for Neuroleptic-Induced Tardive Dyskinesia
Condition: Dyskinesia, Drug-Induced
Intervention: Drug: aripiprazole
Outcome Measures: Total scores of AIMS;   Total scores of PANSS;   Total scores of SAS
9 Recruiting Otolith Function in Patients With Primary Ciliary Dyskinesia
Condition: Primary Ciliary Dyskinesia
Intervention: Other: Utricular centrifugation test, vestibular evoked myogenic potentials & ocular counter-rolling test
Outcome Measure: The results of the utricular centrifugation test, VEMPs & ocular counter-rolling test
10 Recruiting Amantadine and L-DOPA-induced Dyskinesia in Early Parkinson's Disease
Condition: Early Parkinson Disease
Interventions: Drug: Amantadine;   Drug: placebo
Outcome Measures: after 18 months of Phase 1 of the study;   abnormal involuntary dyskinetic movements at the end of phase 3 of the study (wash out);   motor fluctuations after 18 months of Phase 1 of the study;   Time to onset of Dyskinesias
11 Unknown  Efficacy of Docosahexaenoic Acid on Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Dietary Supplement: Omega-3 fish oil capsules (including DHA);   Dietary Supplement: Placebo
Outcome Measures: Clinical rating scales (AIMS, St.Hans);   Quantitative motor testing (kinematic parameters);   Monitoring of psychopathology (Neuro-Psychiatric Inventory, Positive and Negative Syndrome Scale, Calgary Depression Scale for Schizophrenia);   Erythrocyte membrane phospholipid profile (gas chromatography)
12 Unknown  Safety and Efficacy of Pyridoxal 5' -Phosphate in the Treatment of Tardive Dyskinesia
Condition: Tardive Dyskinesia
Interventions: Drug: Pyridoxal 5'-Phosphate;   Drug: Placebo
Outcome Measures: The primary outcome measure will be a reduction in the total AIMS score for items 1 through 7 (facial and oral movements, extremity movements and trunk movements) across treatment groups. .;   An AIMS score reduction (items 1-7) across arms over course of study amongst completers; determine whether the proportion of responders differs between treatment arms; a reduction in the AIMS score, items 1 - 7 total, across treatment arms.
13 Recruiting A Phase 2 Trial Evaluating SNC-102 in Drug-Induced Tardive Dyskinesia
Condition: Drug-induced Tardive Dyskinesia
Interventions: Drug: Acamprosate calcium;   Drug: Placebo
Outcome Measures: Efficacy as measured by changes from baseline in summary scores on the Abnormal Involuntary Movement Scale (AIMS);   Compare the effectiveness of low dose and high dose of SNC-102;   Assess safety and tolerability of SNC-102 in the tardive Dyskinesia population;   Assess the pharmacokinetic (PK) profile in TD subjects;   Determine the relationship between the PK profile and clinical effects of SNC-102
14 Recruiting Reducing Dyskinesia in Parkinson's Disease With Omega-3 Fatty Acids
Condition: Parkinson's Disease
Interventions: Drug: Docosahexaenoic Acid (DHA);   Drug: Placebo
Outcome Measures: Safety/Efficacy of DHA;   Dyskinesia
15 Recruiting Comparison of the Incidence of Dyskinesia in Parkinson`s Disease Who Were Treated With Amantadine or Dopamine Agonist
Condition: Parkinson`s Disease
Intervention:
Outcome Measures: Dyskinesia onset;   UPDRS, severity of Dyskinesia between groups
16 Recruiting D-Serine Treatment For Tardive Dyskinesia
Conditions: Schizophrenia and Schizoaffective Disorder;   Tardive Dyskinesia
Intervention: Dietary Supplement: D-serine
Outcome Measure: Change in AIMS total score
17 Unknown  Early Detection and Characterization of Primary Ciliary Dyskinesia
Condition: Primary Ciliary Dyskinesia
Intervention:
Outcome Measure: Phenotypic and genetic characterization
18 Not yet recruiting Chest Physiotherapy and Lung Function in Primary Ciliary Dyskinesia
Condition: Primary Ciliary Dyskinesia
Intervention: Procedure: Chest physiotherapy
Outcome Measures: Difference in FEV1 before and after treatment;   Difference in LCI before and after chest physiotherapy
19 Unknown  Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide
Condition: Primary Ciliary Dyskinesia
Intervention:
Outcome Measure: Nasal NO < 105 ppb
20 Recruiting Xenazine in Late Dyskinetic Syndrome With Neuroleptics
Condition: Tardive Dyskinesia
Interventions: Drug: Tetrabenazine;   Drug: Placebo
Outcome Measures: Changes in ESRS: Extrapyramidal Symptoms Rating Scale;   Changes in Sub-score ESRS-II;   CGI amelioration;   Tolerance;   Changes in Quality of life;   AIMS improvement;   Changes in intermediate ESRS and post-treatment ESRS